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Performance of the Automated Urinalysis in Diagnosis of Proliferative Glomerulonephritis
To the Editor: The examination of urine to diagnose disease is an age-old practice, dating back thousands of years in primitive forms, and arguably represents the genesis of laboratory medicine. 1 Microscopic evaluation of urine was introduced in the 19th century, and in the 20th century became a cornerstone of the nephrologist's armamentarium for diagnosing kidney disease. Since the introduction of automated urine analyzers, manual examination of the urine sediment has rapidly fallen out of favor among clinicians. 2À4 Despite its central role in the evaluation of patients with kidney disease, limited data are available in the literature on the test performance characteristics of the modern urinalysis (UA) as reported by laboratories using automated analyzers. 5 In a cross-sectional analysis, we studied how well automated UAs distinguished proliferative glomerulonephritis (PGN) from other forms of kidney disease in a cohort of adult patients who had not yet been initiated on immunosuppressive therapy, and for whom clinicopathologic diagnoses were uniformly adjudicated by native kidney biopsies.
RESULTS
A total of 512 patients were included in the analysis, 511 of whom had automated urine test strip results available and 421 of whom had urine red blood cell (RBC) counts available within 30 days before undergoing native kidney biopsy (Supplementary Figure S1 ). Of the 512 patients included in the analysis, 134 had PGN. The most common PGN diagnoses were IgA nephropathy (n ¼ 74), antineutrophil cytoplasmic antibodyÀassociated vasculitis (n ¼ 19), and proliferative forms of lupus nephritis (n ¼ 11). The most common non-PGN diagnoses were diabetic nephropathy (n ¼ 63), membranous nephropathy (n ¼ 38), and secondary focal segmental glomerulosclerosis (n ¼ 35) (Supplementary Table S1 ). The mean age of the cohort was 53.9 AE 15.9 years, 46.3% were female, and 68.6% were white. The median estimated glomerular filtration rate was 44.9 (interquartile range [IQR] 26.3-76.8) ml/ min per 1.73 m 2 , and median proteinuria was 2.0 (IQR 0.6À5.0) g/g creatinine (Table 1) .
Patients with PGN had a median urine RBC count of 18 (IQR 6À60) per high-power field (HPF), whereas those with other forms of kidney disease had a median urine RBC count of 2 (IQR 1À10) per HPF (P < 0.01). Moreover, among the patients with PGN, we found a trend toward higher RBC counts in patients with crescentic disease compared to those without glomerular crescents (median [IQR] 23.5 (11.5À92.5) vs. 15 (4À60) RBCs/HPF, respectively, P ¼ 0.06). Of the patients with PGN, 8.3% had less than 1þ blood on their test strip compared to 43.6% of those with other forms of kidney disease. The Spearman correlation coefficient between test strip blood measurements and the urine RBC count was 0.66. Table 2 demonstrates the performance characteristics of automated urine test strip protein and blood at different thresholds for diagnosis of PGN versus other causes of kidney disease. Table 3 shows the same performance characteristics for quantitative proteinuria measurements and automated urine RBC counts. Figure 1 shows receiver operating characteristic (ROC) curves for diagnosis of PGN versus other causes of kidney disease using test strip blood or the automated urine RBC count as predictors. The areas under these ROC curves were 0.77 and 0.75, respectively. The difference in the ROC curves was not significant when compared among patients who had both tests performed (P ¼ 0.15). Using the laboratory's conventional threshold of >2 RBCs/HPF to define abnormal hematuria, the RBC count had 86% sensitivity, 51% specificity, 39% positive predictive value (PPV), and 91% negative predictive value (NPV) for PGN. Among patients with proteinuria <0.5 g/g creatinine, NPV increased to 96%. Analogously, a negative test strip for blood had 95% sensitivity, 29% specificity, 32% PPV, and 94% NPV. The NPV increased to 96% when restricted to patients with proteniuria <0.5 g/g creatinine.
When test strip blood was added to a clinical prediction model of PGN which included age, sex, race (black vs. nonblack), proteinuria (<1 vs. $1 g/g creatinine), estimated glomerular filtration rate, acute kidney injury as the reason for biopsy, diabetes Table 3 . Sensitivity (Sens), specificity (Spec), positive predictive value (PPV), negative predictive value (NPV), postive likelihood ratio (LRþ), and negative likelihood ratio (LRÀ) for different thresholds of quantitative proteinuria and urine RBC counts for diagnosis of proliferative glomerulonephritis 
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mellitus, hypertension, systemic lupus erythematosus, vasculitis, and hepatitis C, the area under the ROC curve increased from 0.71 for the base model alone up to 0.81 (P < 0.01). Among patients for whom automated urine RBC counts were available, the addition of the RBC count instead of test strip blood to the same clinical prediction model increased the area under the ROC curve from 0.71 to 0.76 (P < 0.01) (Figure 2 ).
DISCUSSION
Our data show that the automated UA has fair ability to differentiate PGN from other kidney diseases. A negative urine RBC count or dipstick for blood had high negative predictive value, especially among patients with low levels of proteinuria, despite our cohort having a high proportion of patients with PGN. Both tests, however, had limited specificity and positive predictive value, and similar performance overall. It is possible that specificity and PPV would be higher in nonbiopsied chronic kidney disease cohorts, as most patients with diseases such as diabetic nephropathy or hypertensive nephrosclerosis do not undergo biopsy, and our cohort is thus likely to be enriched for atypical presentations of these diseases. Although this could affect the generalizability of our findings, the inclusion of only patients with biopsy-proven disease is a fundamental strength of our analysis. Without being able to compare our automated UA results to the results of the gold standard diagnostic method, ascertainment bias could lead to invalid estimates of the test performance characteristics. Despite its limitations as a diagnostic test, the automated UA added significantly to a basic clinical prediction model of PGN. Among patients with PGN, we furthermore found a trend toward an association between higher levels of hematuria and more severe disease, as indicated by the presence of glomerular crescents. Although this finding was not statistically significant, our study may not have been adequately powered to detect a statistically significant difference. Taken together, our data demonstrate quantitatively how the automated UA may aid clinicians, albeit imperfectly, when determining the appropriateness of additional workup for kidney disease, such as serological studies and, ultimately, a kidney biopsy.
Interestingly, we found no difference between the performance characteristics of the urine RBC count and the semiquantitative test strip blood measurements for diagnosis of PGN. Because automated analyzers do not reliably detect less common but more specific features of PGN in the urine sediment, such as acanthocytes and A clinical prediction model of proliferative glomerulonephritis that included age, sex, race (black vs. nonblack), proteinuria (<1 vs. $1 g/g creatinine), estimated glomerular filtration rate, acute kidney injury as the reason for biopsy, diabetes mellitus, hypertension, systemic lupus erythematosus, vasculitis, and hepatitis C significantly improved with the addition of test strip blood (P < 0.01) to the model, as well as with the addition of the sediment red blood cell (RBC) count among patients for whom this was available (P < 0.01). AUC, area under the curve.
RBC casts, 6, 7 further studies are needed to compare the performance characteristics of the manual sediment examination when carried out by trained nephrologists to those of modern laboratory-based automated analyzers. Figure S1 . Overview of analysis cohort. Table S1 . Primary clinicopathologic diagnoses of patients in the analysis cohort.
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Epidemiology and Outcome of CKD in Omani Children
To the Editor: Chronic kidney disease (CKD) is a public health problem worldwide. It is due to permanent kidney damage which ultimately leads to endstage renal disease (ESRD).The Kidney Disease Improving Global Outcomes initiative defines CKD as structural or functional abnormalities of the kidney that last for 3 months or more and affect the well-being of the patient. 1 Children with CKD constitute a small but very important proportion of the CKD population. These children are at risk of long-term complications, such as growth retardation and alteration of cognitive development. [2] [3] [4] There are limited data on the epidemiology of CKD in children, especially for early stages, as most children are asymptomatic. 5 Most earlier studies on pediatric CKD were based on hospital records, largely representing children presenting in late stages, and used different definitions for CKD. 5 More recent publications, however, have been using the CKD classification published by the National Kidney Foundation's Kidney Disease Outcome Quality Initiative in 2003. 6, 7 Oman is one of the Arab Countries located in the southeastern corner of the Arabian Peninsula. According to the 2018 Statistical Yearbook report of the National Center for Statistics and Information, in mid-year 2017, the population size was 4.55 million with a population of approximately 1 million age 14 years and younger. 8 The aim of this study was to establish data about CKD in children in Oman, including the annual incidence, etiology, and long-term outcomes based on the experience at a major tertiary referral center that provides pediatric nephrology services for the entire population being the only pediatric nephrology center catering for children with CKD.
RESULTS
Over a study period of 12 years (between 2004 and 2015) there were 208 cases of CKD, the patient demographics are illustrated in Table 1 .The mean
